Compare · ALLK vs NVO
ALLK vs NVO
Side-by-side comparison of Allakos Inc. (ALLK) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALLK and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $220.35B, about 634.9x ALLK ($347.1M).
- NVO has hit the wire 5 times in the past 4 weeks while ALLK has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 22 for ALLK).
- Company
- Allakos Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $347.1M
- $220.35B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 0
- 5
- Recent ratings
- 22
- 25
Allakos Inc.
Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis. The is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. Allakos Inc. was incorporated in 2012 and is headquartered in Redwood City, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ALLK
- SEC Form 15-12G filed by Allakos Inc.
- Large owner Bvf Partners L P/Il returned 16,312,872 shares to the company (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Allakos Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Allakos Inc.
- SEC Form EFFECT filed by Allakos Inc.
- SEC Form EFFECT filed by Allakos Inc.
- SEC Form S-8 POS filed by Allakos Inc.
- SEC Form S-8 POS filed by Allakos Inc.
- SEC Form S-8 POS filed by Allakos Inc.
- SEC Form S-8 POS filed by Allakos Inc.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S